Care your patients can count on
CrinetiCARE offers personalized support to help your eligible patients throughout their treatment journey with PALSONIFY™ (paltusotine).
Patricia
Living with acromegaly
About CrinetiCARE
CrinetiCARE provides access and reimbursement support to help patients start and stay on therapy with PALSONIFY. From helping your patients navigate insurance coverage to connecting with nurse educators, CrinetiCARE is here to help support access.
Key support services
- Benefits investigation
- Appeals
- Financial support
- Nurse educators
Financial support
CrinetiCARE provides financial assistance programs to help your eligible patients access treatment with PALSONIFY. Our dedicated team works directly with patients and their insurance providers to minimize out-of-pocket costs.
Quick start supply
Patients who experience a delay in their insurance coverage determination can begin therapy while the CrinetiCARE team works on securing insurance coverage.
Copay assistance program
Eligible commercially insured patients who are not insured by any federal or government-funded program may pay as little as $0 for PALSONIFY, with up to $25,000 in annual support.*
Patient assistance program
Eligible uninsured or underinsured patients may be able to receive PALSONIFY at no cost.†
For more information about CrinetiCARE programs, please call 844-CRN-HELP (844-276-4357).
When your patients enroll in CrinetiCARE, we’ll help determine their eligibility and guide them through accessing the financial support they may need.
Megan
Living with acromegaly
Additional support organizations
*Terms and conditions apply. Patients are eligible for copay assistance if enrolled in private commercial health insurance and are not covered by state or federal healthcare programs, and who meet the eligibility criteria. Patients will be enrolled for 12 months. There are no income requirements to participate in the program.
†Criteria include patients who are uninsured or have insurance that excludes coverage for PALSONIFY (including patients on Medicare or Medicaid), residents of the United States or Puerto Rico, and patients who meet the financial eligibility requirements. Terms and conditions apply.
Nurse educators
education, help answer common questions about therapy, and provide consistent, ongoing support throughout your patient’s journey with PALSONIFY.
Your patients can reach a live nurse at
Specialty
pharmacy
Appeals support with CoverMyMeds®
INDICATION:
PALSONIFY is a somatostatin receptor agonist indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS:
- Cholelithiasis and Its Complications: Cholelithiasis, including related complications such as acute cholecystitis and pancreatitis, have been reported. Monitor patients periodically. Discontinue PALSONIFY if complications of cholelithiasis occur and treat appropriately.
- Hyperglycemia and Hypoglycemia: Hyperglycemia, diabetes mellitus, or hypoglycemia, may occur. Monitor blood glucose levels when PALSONIFY treatment is initiated or when dosage is altered. Adjust antidiabetic treatment accordingly.
- Cardiovascular Abnormalities: Cardiac conduction abnormalities and other ECG changes such as PR interval prolongation, bradycardia, sinus arrest, and atrioventricular block may occur in patients with acromegaly and were reported in PALSONIFY clinical trials. Dosage adjustments of concomitant drugs that have bradycardic effects may be necessary.
- Thyroid Function Abnormalities: Somatostatin analogs may suppress the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. Periodic assessment of thyroid function is recommended.
- Steatorrhea and Malabsorption of Dietary Fats: Somatostatin analog treatment may result in malabsorption of dietary fats and subsequent symptoms of steatorrhea, loose stools, abdominal bloating, and weight loss. If new or worsening symptoms are reported with PALSONIFY, evaluate patients for potential pancreatic exocrine insufficiency and manage accordingly.
- Vitamin B12 Deficiency: Vitamin B12 deficiency may occur. Monitor vitamin B12 levels, if clinically indicated.
ADVERSE REACTIONS:
Most common adverse reactions (>5%) are diarrhea, abdominal pain, nausea, decreased appetite, sinus bradycardia, hyperglycemia, palpitations, and gastroenteritis.
DRUG INTERACTIONS:
- Strong or Moderate CYP3A4 Inducers: may decrease PALSONIFY exposure. May require an increased dosage of PALSONIFY.
- Proton Pump Inhibitors: may decrease PALSONIFY exposure. May require an increased dosage of PALSONIFY. Avoid concomitant use of proton pump inhibitors in patients who are already on PALSONIFY 60 mg.
- Cyclosporine: may decrease cyclosporine exposure. May require cyclosporine dosage adjustment when used with PALSONIFY; follow therapeutic monitoring recommendations.
Please report adverse events to Crinetics Pharmaceuticals at 1‑833‑CRN‑INFO (1‑833‑276‑4636) or FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch.
Please see Full Prescribing Information including Patient Information.